Recruitment

Recruitment Status
Recruiting

Inclusion Criterias

At least one measurable lesion according to the RECIST criteria;
Informed consent signed
an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
...
At least one measurable lesion according to the RECIST criteria;
Informed consent signed
an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
Adequate bone marrow, cardiac, liver, and renal function;
Age: 18-80 years;
Life expectancy ≥2 months;
Not received other anti-tumor treatment
histologically confirmed with malignant tumor;

Exclusion Criterias

Uncontrolled central nervous system metastases;
previous history of other malignancies;
Serious or uncontrolled concurrent medical illness.
Uncontrolled central nervous system metastases;
previous history of other malignancies;
Serious or uncontrolled concurrent medical illness.

Summary

Conditions
Malignant Tumor
Type
Interventional
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 80 years
Gender
Both males and females

Description

The patients with malignant tumor are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) . Venous blood (4 ml) is collected from each subject and placed into tubes containing Ethylene Diamine Tetraacetic Acid(EDTA) before and after each treatment. Lymphocytes are sorted by Fl...

The patients with malignant tumor are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) . Venous blood (4 ml) is collected from each subject and placed into tubes containing Ethylene Diamine Tetraacetic Acid(EDTA) before and after each treatment. Lymphocytes are sorted by Fluorescence Activated Cell Sorting(FACS) and stored at -80°C until processing. The T-Cell Receptor/B-Cell Receptor gene expression is detected by micro-array。 Estimate Immunotherapy response, time to disease progression, survival rates and clinical benefit response on patients. Response is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines. Degree of response is used to divide the cancers into two groups: sensitive and non-sensitive to immunotherapy. Compare the gene expression profile between different immunotherapy response groups to explore the mechanism that predict the DC-CIK immunotherapy response.

Inclusion Criterias

At least one measurable lesion according to the RECIST criteria;
Informed consent signed
an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
...
At least one measurable lesion according to the RECIST criteria;
Informed consent signed
an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
Adequate bone marrow, cardiac, liver, and renal function;
Age: 18-80 years;
Life expectancy ≥2 months;
Not received other anti-tumor treatment
histologically confirmed with malignant tumor;

Exclusion Criterias

Uncontrolled central nervous system metastases;
previous history of other malignancies;
Serious or uncontrolled concurrent medical illness.
Uncontrolled central nervous system metastases;
previous history of other malignancies;
Serious or uncontrolled concurrent medical illness.

Locations

Beijing, 100038
Beijing, 100038

Tracking Information

NCT #
NCT01906632
Collaborators
Not Provided
Investigators
Not Provided